## **Bevacizumab** AURELIA



## Bevacizumab AURELIA **Bevacizumab AURELIA** PRFLIMINARY SCORE **SCORE CURATIVE CURATIVE** Overall Survival / Disease-Free Survival / Pathological Complete Response **NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival Improved QoL Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response Other adjustments INFORMATION Tumour type: Gynaecological Malignancies Therapeutic Indication: In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinumresistant recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who received ≤2 prior ChT regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents Experimental Arm: Bevacizumab + Chemotherapy Control Arm: Paclitaxel or topotecan or liposomal doxorubicin



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.